Login / Signup
Hitomi Ajimizu
ORCID
Publication Activity (10 Years)
Years Active: 2023-2024
Publications (10 Years): 3
Top Topics
Combination Therapy
Early Stage
Tyrosine Kinase
Mesenchymal Stem Cells
Top Venues
Mediastinum (Hong Kong, China)
Molecular cancer therapeutics
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Hitomi Ajimizu
,
Yuichi Sakamori
Narrative review of indication and management of induction therapy for thymic epithelial tumors.
Mediastinum (Hong Kong, China)
8 (2024)
Hitomi Ajimizu
,
Yuichi Sakamori
Narrative review of indication and management of induction therapy for thymic epithelial tumors.
Mediastinum (Hong Kong, China)
8 (2024)
Tatsuya Ogimoto
,
Hiroaki Ozasa
,
Takahiro Tsuji
,
Tomoko Yamamoto Funazo
,
Masatoshi Yamazoe
,
Kentaro Hashimoto
,
Hiroshi Yoshida
,
Kazutaka Hosoya
,
Hitomi Ajimizu
,
Takashi Nomizo
,
Hironori Yoshida
,
Masatsugu Hamaji
,
Toshi Menju
,
Akihiko Yoshizawa
,
Hiroshi Date
,
Toyohiro Hirai
Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer.
Molecular cancer therapeutics
(2023)